Therapeutic options for severe asthma

Archives of Medical Science

Volumn 8, Issue 4, 2012, Pages 589-597

  Mathew, Jilcy ^a   Aronow, Wilbert S ^a   Chandy, Dipak ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Severe asthma; Treatment

Indexed keywords

ALLERGEN; ANTIINFECTIVE AGENT; AURANOFIN; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; GOLIMUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; OMALIZUMAB; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; TACROLIMUS; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; WARFARIN; ZILEUTON;

ASTHMA; BRONCHIAL THERMOPLASTY; DISEASE SEVERITY; DRUG DOSE COMPARISON; GASTROESOPHAGEAL REFLUX; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; OBESITY; PATIENT COMPLIANCE; PHYSICAL MEDICINE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SLEEP DISORDERED BREATHING; SMOKING;

EID: 84866870319     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.30280     Document Type: Review

References (122)

1. de Marco R, Cappa V, Accordini S, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J 2012; 39: 883-92
2. Ma J, Xiao L, Knowles SB. Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. Allergy 2010; 65: 1455-63.
3. Takizawa H. Impact of air pollution on allergic diseases. Korean J Intern Med 2011; 26: 262-73.
4. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78.
5. O'Byrne PM. Global guidelines for asthma management: Summary of the current status and future challenges. Pol Arch Med Wewn 2010; 120: 511-7.
6. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23: 723-9. (Pubitemid 38618143)
7. Herjavecz I, Nagy GB, Gyurkovits K, et al. Cost, morbidity, and control of asthma in hungary: the hunair study. J Asthma 2003; 40: 673-81. (Pubitemid 37296155)
8. Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in spain. J Investig Allergol Clin Immunol 2011; 21: 466-71.
9. Siroux V, Pin I, Pison C, Kauffmann F. Severe asthma in the general population: Definition and prevalence. Rev Mal Respir 2004; 21: 961-9. (Pubitemid 39647901)
10. Thomson CC, Clark S, Camargo CA Jr; MARC Investigators. Body mass index and asthma severity among adults presenting to the emergency department. Chest 2003; 124: 795-802. (Pubitemid 37123292)
11. Kent BD, Lane SJ. Twin epidemics: asthma and obesity. Int Arch Allergy Immunol 2011; 157: 213-4.
12. Kilic H, Oguzulgen IK, Bakir F, Turktas H. Asthma in obese women: Outcomes and factors involved. J Investig Allergol Clin Immunol 2011; 21: 290-6.
13. Lugogo NL, Bappanad D, Kraft M. Obesity, metabolic dysregulation and oxidative stress in asthma. Biochim Biophys Acta 2011; 1810: 1120-6.
14. Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011; 127: 741-9.
15. Shore SA, Johnston RA. Obesity and asthma. Pharmacol Ther 2006; 110: 83-102. (Pubitemid 43248727)
16. Hernandez Romero A, Matta Campos J, Mora Nieto A, et al. Clinical symptom relief in obese patients with persistent moderate asthma secondary to decreased obesity. Rev Alerg Mex 2008; 55: 103-11. (Pubitemid 352018942)
17. Reddy RC, Baptist AP, Fan Z, Carlin AM, Birkmeyer NJ. The effects of bariatric surgery on asthma severity. Obes Surg 2011; 21: 200-6.
18. Wang J, Visness CM, Calatroni A, Gergen PJ, Mitchell HE, Sampson HA. Effect of environmental allergen sensitization on asthma morbidity in inner-city asthmatic children. Clin Exp Allergy 2009; 39: 1381-9.
19. Di Giampaolo L, Cavallucci E, Braga M, et al. The persistence of allergen exposure favors pulmonary function decline in workers with allergic occupational asthma. Int Arch Occup Environ Health 2012; 85: 181-8.
20. Rijssenbeek-Nouwens LH, Bel EH. High-altitude tre atment: a therapeutic option for patients with severe, refractory asthma? Clin Exp Allergy 2011; 41: 775-82.
21. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320-5.
22. Strine TW, Balluz LS, Ford ES. The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population. J Asthma 2007; 44: 651-8. (Pubitemid 47621476)
23. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the busselton health study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-14. (Pubitemid 40105408)
24. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783-90. (Pubitemid 46631789)
25. Kupczyk M, Kuprys I, Gorski P, Kuna P. Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma. Ann Allergy Asthma Immunol 2004; 92: 453-8. (Pubitemid 39077588)
26. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116: 970-5. (Pubitemid 41571774)
27. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. european network on aspirin-induced asthma. Eur Respir J 2000; 16: 432-6.
28. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Gar-cia- Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003; 13: 20-5. (Pubitemid 36781519)
29. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxyge nase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005; 95: 154-8. (Pubitemid 41170176)
30. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004; 59: 289-94. (Pubitemid 38339845)
31. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9-14. (Pubitemid 34053350)
32. Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008; 21: 134-41.
33. Nguyen LP, Singh B, Okulate AA, et al. Complementary anti-inflammatory effects of a beta-blocker and a corticosteroid in an asthma model. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 203-10.
34. Kloepfer KM, Gern JE. Virus/allergen interactions and exacerbations of asthma. Immunol Allergy Clin North Am 2010; 30: 553-63, vii.
35. Busse WW, Peters SP, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol 2011; 127: 130-7, 137.e1-3.
36. Vaughn JA, Miller RA. Update on immunizations in adults. Am Fam Physician 2011; 84: 1015-20.
37. Nakashima T, Yokoyama A, Ohnishi H, et al. Chronic hepatitis C virus infection is associated with more severe asthma. Allergol Int 2011; 60: 299-304.
38. Peters J, Singh H, Brooks EG, et al. Persistence of com-munity- acquired respiratory distress syndrome toxin-producing mycoplasma pneumoniae in refractory asthma. Chest 2011; 140: 401-7.
39. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest 2002; 121: 1782-8. (Pubitemid 34634396)
40. Specjalski K, Jassem E. Chlamydophila pneumoniae, mycoplasma pneumoniae infections, and asthma control. Allergy Asthma Proc 2011; 32: 9-17.
41. Black PN, Scicchitano R, Jenkins CR, et al. Serological evidence of infection with chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15: 254-9. (Pubitemid 30085949)
42. Horiguchi T, Miyazaki J, Ohira D, et al. Usefulness of sparfloxacin against chlamydia pneumoniae infection in patients with bronchial asthma. J Int Med Res 2005; 33: 668-76. (Pubitemid 43009594)
43. Gamble J, Stevenson M, Heaney LG. A study of a multilevel intervention to improve non-adherence in difficult to control asthma. Respir Med 2011; 105: 1308-15.
44. Dalcin Pde T, Grutcki DM, Laporte PP, et al. Impact of a short-term educational intervention on adherence to asthma treatment and on asthma control. J Bras Pneumol 2011; 37: 19-27.
45. Apter AJ, Wang X, Bogen DK, et al. Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 516-23.e1-5.
46. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax 2012; 67: 268-70.
47. Mazzei CM, Lasala FG, Ambrosio JA. The effect of betamethasone dipropionate injectable on chronic bronchial asthma. J Int Med Res 1981; 9: 138-42. (Pubitemid 11153969)
48. Chan JS, Cowie RL, Lazarenko GC, Little C, Scott S, Ford GT. Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma. Can Respir J 2001; 8: 147-52. (Pubitemid 32655348)
49. Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 2000; 136: 298-303. (Pubitemid 30470950)
50. Bhatnagar SK. Can single dose intramuscular dexamethasone replace five day oral prednisolone therapy in mild to moderate asthma cases? Indian Pediatr 2000; 37: 1158-9.
51. Butler C, Heaney LG. Risk factors of frequent exa cerbations in difficult-to-treat asthma. Eur Respir J 2006; 27: 1324-5. (Pubitemid 44914322)
52. Bor S, Kitapcioglu G, Solak ZA, Ertilav M, Erdinc M. Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease. J Gastroenterol Hepatol 2010; 25: 309-13.
53. Lee YB, Lim JH, Choi YJ, et al. Effects of proton pump inhibitors in asthmatics with gastroesophageal reflux disease. Korean J Gastroenterol 2011; 58: 178-83.
54. Sharma B, Sharma M, Daga MK, Sachdev GK, Bondi E. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J Gastroenterol 2007; 13: 1706-10. (Pubitemid 46711342)
55. Teodorescu M, Polomis DA, Hall SV, et al. Association of obstructive sleep apnea risk with asthma control in adults. Chest 2010; 138: 543-50.
56. Kheirandish-Gozal L, Dayyat EA, Eid NS, Morton RL, Gozal D. Obstructive sleep apnea in poorly controlled asthmatic children: effect of adenotonsillectomy. Pediatr Pulmonol 2011; 46: 913-8.
57. Malakasioti G, Gourgoulianis K, Chrousos G, Kaditis A. Interactions of obstructive sleep-disordered breathing with recurrent wheezing or asthma and their effects on sleep quality. Pediatr Pulmonol 2011; 46: 1047-54.
58. Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, et al. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: a multicenter retrospective study. Am J Respir Crit Care Med 2010; 182: 676-83.
59. Brzecka A, Pawelec-Winiarz M, Piesiak P, Nowak E, Jankowska R. Suppression of chronic nocturnal cough during continuous positive airway pressure (CPAP) treatment in a patient with asthma and obstructive sleep apnea syndrome. Pneumonol Alergol Pol 2011; 79: 121-6.
60. Lafond C, Series F, Lemiere C. Impact of CPAP on asthmatic patients with obstructive sleep apnoea. Eur Respir J 2007; 29: 307-11. (Pubitemid 46231908)
61. Xue Z, Yu Y, Gao H, Gunst SJ, Tepper RS. Chronic continuous positive airway pressure (CPAP) reduces airway reactivity in vivo in an allergen-induced rabbit model of asthma. J Appl Physiol 2011; 111: 353-7.
62. Boulet LP, Boulay ME. Asthma-related comorbidities. Expert Rev Respir Med 2011; 5: 377-93.
63. Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG. Allergic rhinitis and sinusitis in asthma: differential effects on symptoms and pulmonary function. Chest 2006; 130: 429-35. (Pubitemid 44267009)
64. Castillo Vizuete JA, Mullol Miret J. Rhinitis and asthma comorbidity in spain: the RINAIR study. Arch Bronconeumol 2008; 44: 597-603.
65. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; 4: CD005533.
66. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010; 4: CD005533.
67. Kaur M, Chivers JE, Giembycz MA, Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 2008; 73: 203-14. (Pubitemid 350294211)
68. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009; 65: 853-71.
69. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100: 1307-17. (Pubitemid 43942329)
70. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007; 20: 23-35. (Pubitemid 44648798)
71. Scichilone N, Battaglia S, Sorino C, et al. Effects of extrafine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010; 65: 897-902.
72. Paggiaro P. New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine. Open Respir Med J 2009; 3: 38-42.
73. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 2009; 5: 639-58.
74. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-6. (Pubitemid 36307998)
75. Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother 2011; 12: 2119-28.
76. O'Connor BJ, Lofdahl CG, Balter M, Szczeklik A, Boulet LP, Cairns CB. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med 2007; 101: 1088-96. (Pubitemid 46667685)
77. Mastalerz L, Kumik J. Antileukotriene drugs in the tre at- ment of asthma. Pol Arch Med Wewn 2010; 120: 103-8.
78. Wang Y, Wang CZ, Lin KX, et al. Comparison of inhaled corticosteroid combined with theophylline and doubledose inhaled corticosteroid in moderate to severe asthma. Respirology 2005; 10: 189-95. (Pubitemid 40638003)
79. Makino S, Adachi M, Ohta K, et al. A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD. Allergol Int 2006; 55: 395-402. (Pubitemid 46065429)
80. Kapoor AS, Olsen SR, O'Hara C, Puttagunta L, Vethanayagam D. The efficacy of tiotropium as a steroidsparing agent in severe asthma. Can Respir J 2009; 16: 99-101.
81. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-14.
82. Domingo Ribas C, Comet Monte R, Bosque Garcia M, Moron Besoli A, Monton Soler C. Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients. Rev Clin Esp 1999; 199: 142-6. (Pubitemid 29185698)
83. Comet R, Domingo C, Larrosa M, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med 2006; 100: 411-9. (Pubitemid 43239875)
84. Aaron SD, Dales RE, Pham B. Management of steroiddependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med 1998; 92: 1059-65. (Pubitemid 28416838)
85. Attar SM. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study. Saudi Med J 2010; 30: 909-15.
86. Coren ME, Rosenthal M, Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997; 77: 522-3. (Pubitemid 28016374)
87. Balfour-Lynn I. Difficult asthma: beyond the guidelines. Arch Dis Child 1999; 80: 201-6. (Pubitemid 29119741)
88. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324-8.
89. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-14. (Pubitemid 26051322)
90. Mungan D, Misirligil Z, Sin B, Kaya A, Demirel Y, Gurbuz L. Cyclosporin in steroid dependent asthma. Allergol Immunopathol (Madr) 1995; 23: 202-6.
91. Taniguchi H, Tokui K, Iwata Y, Abo H, Izumi S. A case of severe bronchial asthma controlled with tacrolimus. J Allergy (Cairo) 2011; 2011: 479129.
92. Saadeh C, Urban RS. Azathioprine in the treatment of chronic refractory steroid-dependent asthma. South Med J 1993; 86: 94-5.
93. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2004; 1: CD003270.
94. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroiddependent asthma auranofin multicenter drug trial. J Allergy Clin Immunol 1996; 98: 317-24. (Pubitemid 26326126)
95. Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010; 105: 313-9.
96. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an openlabel study. Respir Med 2008; 102: 1371-8.
97. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16. (Pubitemid 40293346)
98. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009; 103: 1633-42.
99. Bang LM, Plosker GL. Omalizumab: a review of its use in the management of allergic asthma. Treat Respir Med 2004; 3: 183-99. (Pubitemid 39004404)
100. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003; 112: 563.
101. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816.
102. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422.
103. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088.
104. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
105. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-71. (Pubitemid 350223751)
106. Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010; 125: 803-13.
107. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-93.
108. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178: 1002-8.
109. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a rando mised, controlled trial. Eur Respir J 2011; 37: 1352-9.
110. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63: 584-91. (Pubitemid 351969250)
111. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-58.
112. Ball HA, Van Scott MR, Robinson CB. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin Rev Allergy Immunol 2004; 27: 207-17. (Pubitemid 40216081)
113. Sandrasagra A, Tang L, Leonard SA, et al. RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Expert Opin Biol Ther 2001; 1: 979-83.
114. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110-7. (Pubitemid 43348344)
115. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-75. (Pubitemid 40091808)
116. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96: 679-86.
117. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148-55.
118. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the fungal asthma sensitization trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-8.
119. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, Sterk PJ. Effect of inhaled heparin on aller-gen- induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996; 153: 1790.
120. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; 2: CD002985.
121. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, doubleblind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-24.
122. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006; 173: 965-9.